Miro1 (Mitochondrial Rho GTPase 1) modulation therapy is an emerging experimental approach for neurodegenerative diseases that targets mitochondrial quality control mechanisms. By modulating Miro1, a key mitochondrial anchor protein, therapies aim to enhance mitophagy—the process by which damaged mitochondria are selectively removed—thus addressing mitochondrial dysfunction, a central contributor to neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[1][2].
Miro1 serves as a critical regulator of mitochondrial dynamics, controlling mitochondrial transport, quality control, and the initiation of mitophagy through its interaction with the PINK1/Parkin pathway. Dysregulation of Miro1 has been implicated in multiple neurodegenerative diseases, making it an attractive therapeutic target[^3].
Miro1 is a calcium-binding GTPase localized to the outer mitochondrial membrane that acts as a molecular anchor regulating mitochondrial transport along cytoskeletal tracks. Under normal conditions, Miro1 facilitates the movement of mitochondria within neurons, ensuring proper distribution of energy-producing organelles to regions with high metabolic demand[^4].
Key functions of Miro1:
The PINK1/Parkin pathway is the primary mechanism for ubiquitin-mediated mitophagy:
Miro1 removal is a critical early step in mitophagy, as it disconnects damaged mitochondria from the transport machinery and marks them for degradation[^5].
Several approaches are being developed to modulate Miro1 for therapeutic benefit:
| Strategy | Mechanism | Status |
|---|---|---|
| Miro1 degradation | Enhance PINK1/Parkin-mediated Miro1 clearance | Preclinical |
| Miro1 knockdown | Reduce Miro1 expression to promote mitophagy | Preclinical |
| Miro1 stabilizers | Prevent excessive Miro1 removal | Research |
| PINK1 activators | Upstream enhancement of mitophagy | Phase 1/2 |
In AD models, Miro1 modulation has shown promise:
PD has the strongest preclinical evidence for Miro1-targeted therapy:
ALS research shows mitochondrial dysfunction is an early event:
As of 2026, no Miro1-targeted therapies have reached clinical trials. However, related approaches are in development:
| Company | Approach | Target | Stage |
|---|---|---|---|
| Various | PINK1 activators | Upstream mitophagy | Preclinical |
| Research groups | Gene therapy (Miro1 knockdown) | Miro1 | Preclinical |
| Multiple | NAD+ boosters | Sirtuins/Mitophagy | Phase 2 |
The field is moving toward combination approaches that target multiple nodes of the mitophagy pathway[^9].
Preclinical studies suggest acceptable safety: